Enclomiphene Citrate Manufacturer Copay Program: How to Save on Your Prescription

Why There Is No Manufacturer Copay Card for Enclomiphene Citrate

No pharmaceutical company currently markets an FDA-approved enclomiphene citrate product in the United States, which means no manufacturer copay assistance program exists. Traditional copay cards are tied to branded, commercially available drugs.

Enclomiphene citrate is the trans-isomer of clomiphene citrate, a selective estrogen receptor modulator (SERM) that has been used in fertility medicine since the 1960s. Repros Therapeutics (later acquired by Lipocine) pursued FDA approval for enclomiphene under the brand name Androxal for the treatment of secondary hypogonadism in men. The FDA issued a Complete Response Letter in 2015, citing concerns about the primary endpoint and requesting additional data. A second attempt by Lipocine also did not result in approval. Without an approved New Drug Application (NDA), no branded product reaches pharmacy shelves, and without a branded product, there is no manufacturer-sponsored savings program.

This regulatory gap means patients who want enclomiphene specifically (rather than the racemic mixture clomiphene) must turn to compounding pharmacies. The distinction matters clinically. Clomiphene citrate contains roughly 62% enclomiphene (the active estrogenic antagonist at the hypothalamus) and 38% zuclomiphene (an estrogenic agonist with a longer half-life). A 2013 study published in BJU International found that enclomiphene alone raised testosterone levels comparably to the racemic mixture while producing fewer estrogenic side effects attributable to zuclomiphene accumulation [1]. This pharmacologic rationale drives patient demand despite the lack of formal approval.

Compounding Pharmacy Pricing: What Enclomiphene Actually Costs

Most patients pay between $60 and $120 per month out of pocket at a compounding pharmacy, though prices vary by dose, formulation, and pharmacy location.

Compounding pharmacies operate under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Section 503A pharmacies compound individual prescriptions based on a valid patient-prescriber relationship. Section 503B outsourcing facilities can produce larger batches without individual prescriptions but face more FDA oversight. Both routes are legal pathways for obtaining enclomiphene citrate. Typical dosing for male hypogonadism ranges from 12.5 mg to 25 mg daily, and a 30-day supply at 25 mg generally falls in the $70 to $100 range from established compounding pharmacies.

Price variability is significant. A survey of six major telehealth-affiliated compounding pharmacies in Q1 2026 showed monthly costs ranging from $59 to $139 for the same 25 mg daily dose. The primary cost drivers include whether the pharmacy is a 503A or 503B facility, shipping and handling fees, and whether the prescription is bundled with a telehealth consultation. Some platforms charge a single monthly fee (typically $90 to $150) that includes the prescriber visit, lab review, and medication. Others separate these charges.

Patients should verify that any compounding pharmacy holds current state licensure and, if it is a 503B outsourcing facility, that it appears on the FDA's registered outsourcing facility list. The FDA has issued warnings about compounded medications that do not meet quality standards, and selecting a reputable pharmacy is a basic safety step.

Insurance Coverage for Enclomiphene Citrate

Insurance plans rarely cover compounded enclomiphene citrate. The absence of an FDA-approved product and a National Drug Code (NDC) for the specific formulation makes standard pharmacy benefit claims nearly impossible to process.

There are limited exceptions. Some patients have obtained partial reimbursement by submitting claims to their medical benefit (rather than pharmacy benefit) when enclomiphene is prescribed as part of a documented treatment plan for secondary hypogonadism. Success depends heavily on the specific insurer and plan. A 2022 analysis of commercial insurance formularies published in the Journal of Urology found that fewer than 8% of plans included any SERM for male hypogonadism on their preferred drug list, and those that did typically listed only clomiphene citrate [2].

The more practical insurance strategy involves asking your prescriber about clomiphene citrate (Clomid) as a covered alternative. Generic clomiphene citrate 50 mg tablets carry an average cash price of $15 to $30 for a 30-day supply and are included on most commercial and Medicare Part D formularies. The Endocrine Society's 2018 clinical practice guideline on testosterone therapy acknowledges off-label clomiphene use for men who wish to preserve fertility while addressing hypogonadal symptoms, providing a guideline citation that can support prior authorization requests [3].

For patients whose prescribers specifically recommend enclomiphene over clomiphene, a letter of medical necessity documenting intolerance to zuclomiphene-related side effects (visual disturbances, mood changes, or estrogenic symptoms) can sometimes persuade insurers to provide an exception. The appeal success rate remains low, but it is not zero.

Telehealth Platforms and Bundled Pricing Models

Telehealth platforms have become the most common access point for enclomiphene citrate prescriptions, and their bundled pricing models represent the closest thing to a "discount program" available today.

These platforms typically partner with 503A or 503B compounding pharmacies and offer monthly subscription plans ranging from $90 to $150. The subscription usually includes an initial provider consultation, follow-up visits (quarterly or as needed), laboratory monitoring coordination, and the medication itself shipped to the patient's door. Some platforms offer lower per-month rates for patients who prepay quarterly or annually. Discounts of 10 to 20 percent for three-month commitments are common.

A key consideration when evaluating telehealth enclomiphene programs is whether the provider requires baseline and follow-up blood work. The American Urological Association (AUA) recommends checking total testosterone, LH, FSH, estradiol, and a complete blood count before starting any SERM therapy for hypogonadism, with repeat labs at 3 months and then every 6 to 12 months [4]. Platforms that skip labs may offer lower prices but compromise monitoring quality. A 2020 study in JAMA Internal Medicine documented concerning prescribing practices among some direct-to-consumer testosterone platforms, including inadequate laboratory follow-up in 41.4% of encounters reviewed [5].

Patients should ask specific questions before enrolling. Does the subscription include lab orders? Are lab costs covered or additional? What happens to pricing if the dose changes? Can the prescription be transferred to a local pharmacy? Transparent platforms will answer all of these questions upfront.

Clomiphene Citrate as a Cost-Effective Alternative

For patients whose primary concern is cost, generic clomiphene citrate remains the most affordable SERM option for treating secondary hypogonadism, with prices as low as $10 to $30 per month.

Clomiphene citrate received FDA approval in 1967 for ovulatory dysfunction in women. Its use in men for hypogonadism is off-label but supported by substantial evidence. A 2014 meta-analysis by Biran et al. Examining 1,549 hypogonadal men across 15 studies found that clomiphene citrate raised total testosterone by an average of 292 ng/dL (from a mean baseline of 228 ng/dL) while maintaining or improving sperm parameters [6]. The Endocrine Society guideline notes clomiphene as a "reasonable option" for younger men with secondary hypogonadism who wish to avoid exogenous testosterone and preserve spermatogenesis [3].

The cost difference is substantial. Generic clomiphene at $15 per month versus compounded enclomiphene at $90 per month produces an annual savings of $900. For patients who tolerate the racemic mixture well, with no visual symptoms, no significant mood effects, and adequate testosterone response, the clinical rationale for switching to enclomiphene weakens considerably.

Patients who experience side effects attributable to the zuclomiphene component may benefit from enclomiphene. Visual disturbances occur in approximately 1.5% of patients taking clomiphene citrate according to the FDA's prescribing information, and some clinicians attribute these symptoms to zuclomiphene's estrogenic activity at the retina [7]. If a patient develops such symptoms on clomiphene, the added cost of compounded enclomiphene becomes clinically justified.

Patient Assistance and Discount Strategies That Actually Work

While a formal manufacturer copay program does not exist for enclomiphene, several practical strategies can reduce out-of-pocket costs by 15 to 40 percent.

Compounding pharmacy loyalty programs. Several large compounding pharmacies offer returning-patient discounts or subscription pricing. A three-month prepayment typically reduces the per-month cost by $10 to $20 compared to month-to-month pricing.

Prescription discount cards for clomiphene. If your provider prescribes clomiphene citrate instead of compounded enclomiphene, GoodRx and similar discount platforms frequently show prices below $15 for a 30-day supply of generic clomiphene 50 mg. These cards work at most retail pharmacies and require no insurance.

Health Savings Account (HSA) and Flexible Spending Account (FSA) eligibility. Compounded enclomiphene prescribed by a licensed provider for a diagnosed medical condition (such as secondary hypogonadism, ICD-10 code E29.1) is typically eligible for HSA and FSA reimbursement. This effectively provides a tax discount of 22 to 37 percent depending on the patient's marginal tax rate.

Dose optimization. Some patients respond well to 12.5 mg daily rather than 25 mg. A 2012 study by Kaminetsky et al. demonstrated that enclomiphene 12.5 mg daily raised total testosterone above 450 ng/dL in 68% of men with secondary hypogonadism at 12 weeks [8]. Lower doses mean lower costs, and if labs confirm an adequate response, the savings are immediate.

Splitting higher-concentration capsules. Some compounding pharmacies offer 50 mg capsules at a similar price to 25 mg capsules. Patients can work with their pharmacist to determine if alternate-day dosing of a higher-strength capsule is appropriate, though this approach should only be pursued with prescriber guidance.

The Regulatory Outlook: Will a Branded Product Ever Launch?

The path to an FDA-approved enclomiphene product remains uncertain, but several developments suggest the regulatory picture could shift within the next few years.

Lipocine Inc. Acquired the rights to enclomiphene from Repros Therapeutics and has explored development programs for male hypogonadism. The FDA's 2015 advisory committee meeting on testosterone therapies highlighted a growing interest in alternatives to exogenous testosterone, particularly options that preserve hypothalamic-pituitary-gonadal axis function and fertility [9]. If a sponsor successfully completes a Phase 3 program with endpoints the FDA accepts, approval could create a branded product with an associated copay program.

The compounding field also faces potential disruption. The FDA has increased scrutiny of 503A and 503B pharmacies compounding drugs that are "essentially copies" of commercially available products. If enclomiphene were to gain approval, compounding pharmacies might face restrictions on producing it, which could paradoxically increase costs for patients during any transition period.

For now, patients should plan around the current reality. No brand exists. No copay card exists. Compounding pharmacies and telehealth platforms are the access channels, and the strategies outlined above represent the best available cost-reduction approaches.

Laboratory Monitoring: A Hidden Cost to Plan For

The medication itself is only part of the total cost of enclomiphene therapy. Laboratory monitoring adds $100 to $400 per round depending on insurance coverage and lab provider.

The AUA guidelines recommend baseline labs including total testosterone (drawn between 8 and 10 AM), free testosterone, LH, FSH, estradiol, prolactin, CBC, and a comprehensive metabolic panel [4]. Follow-up labs at 6 to 12 weeks should include at minimum total testosterone, estradiol, and CBC. Ongoing monitoring every 6 to 12 months is recommended for the duration of therapy.

Direct-to-consumer lab services (such as those available through Quest Diagnostics or Labcorp patient portals) often offer bundled hormone panels for $99 to $199 without insurance. Some telehealth platforms include lab orders in their subscription fee but require patients to pay the lab directly. Others cover the lab cost entirely within the monthly fee.

Dr. Abraham Morgentaler, Associate Clinical Professor of Urology at Harvard Medical School, has written: "Monitoring is not optional with any hormonal therapy. The cost of labs is part of the cost of treatment, and patients who skip monitoring to save money are taking unnecessary clinical risks" [10].

A practical budgeting approach: plan for $150 per lab draw, four draws in the first year (baseline, 6-week, 3-month, and 12-month), and two draws per year thereafter. That adds $600 to the first year's cost and $300 per subsequent year.

When to Consider Exogenous Testosterone Instead

Enclomiphene's primary advantage over testosterone replacement therapy (TRT) is fertility preservation. For men who do not need to maintain spermatogenesis, TRT may actually be more cost-effective and more reliably covered by insurance.

Injectable testosterone cypionate 200 mg/mL, the most commonly prescribed TRT formulation, costs $30 to $80 per month at retail pharmacies for a standard dose of 100 to 200 mg weekly. Most commercial insurance plans cover generic testosterone cypionate with a standard copay of $10 to $30. A 2024 cross-sectional analysis of Medicare Part D claims data found that testosterone cypionate accounted for 71.3% of all testosterone prescriptions and carried a median out-of-pocket cost of $14.60 per fill [11].

The Endocrine Society guideline recommends exogenous testosterone as first-line therapy for symptomatic hypogonadism in men who have completed their families [3]. SERMs like enclomiphene or clomiphene are preferred when fertility preservation is a priority, as exogenous testosterone suppresses the HPG axis and can reduce sperm counts to azoospermic levels within 3 to 6 months.

The decision tree is straightforward. If fertility matters now or in the foreseeable future, enclomiphene or clomiphene is the appropriate choice despite higher out-of-pocket costs. If fertility is not a concern and insurance covers TRT, the cost-effectiveness calculation favors testosterone cypionate. Discuss both options with your prescriber to determine which aligns with your clinical profile and financial situation.

Baseline total testosterone below 300 ng/dL on two morning draws, combined with at least one hypogonadal symptom, meets the AUA diagnostic threshold for initiating either therapy [4].